# FORM 6-K

# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# **Report of Foreign Private Issuer** Pursuant to Rule 13a-16 under the Securities Exchange Act of 1934

For the month ended April, 2012

# **ICON plc**

(Registrant's name)

0-29714 (Commission file number)

South County Business Park, Leopardstown, Dublin 18, Ireland (Address of principal executive offices)

Brendan Brennan, CFO South County Business Park Leopardstown, Dublin 18, Ireland. Brendan.Brennan@iconplc.com 0011-353-1-291-2000 (Name, telephone number, email and/or facsmile number and address of Company contact person)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Yes X No\_\_\_\_

Indicate by check mark whether the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes

Indicate by check mark whether the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes\_\_\_\_\_

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes\_\_\_\_

No<u>X</u>

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):82 N/A

No X

No X

# EXHIBIT LIST

# Exhibit Description

99.1 Icon plc Press Release dated April 24, 2012.

# SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ICON plc

Date: April 24, 2012

<u>/s/ Brendan Brennan</u> Brendan Brennan Chief Financial Officer

# **1st Quarter Results**

DUBLIN--(BUSINESS WIRE)--April 24, 2012--

# ICON reports a 10% increase in first quarter 2012 revenue to \$252m, up 10% year on year, EPS of 15 cents, net new business awards of \$385 million and a B:B of 1.5. (NASDAQ:ICLR) (ISIN:IE0005711209)

# Highlights – First Quarter Fiscal 2012.

- \* Q1 net revenues increased 10% year on year to \$252 million.
- \* Q1 operating income was 5% or \$11.7 million.
- \* EPS for Q1 was 15 cents.

\* Q1 gross business wins \$485 million, net business awards of \$385 million, and a book-to-bill of 1.5.

**Dublin, Ireland, April 24, 2012 – ICON (NASDAQ: ICLR) (ISIN:IE0005711209)**, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the first quarter ended March 31, 2012.

For the first quarter net revenues grew 10% year on year to \$252.3 million from \$229.3 in Q1 2011.

Operating income was \$11.7 million representing 4.6% of revenue, this compared to \$16.0 million (excluding non-recurring items of \$5.0 million) or 7% of revenue for the same quarter last year (4.8% including non-recurring items).

Net income was \$9.0 million compared with \$12.8 million last year (excluding non-recurring items) or 15 cents per share compared to 21 cents in the same quarter last year (14 cents including non-recurring items).

Days sales outstanding, comprising accounts receivable and unbilled revenue less payments on account was 37 days at March 31, 2012 compared with 47 days at December 31, 2011 and 49 days at March 31, 2011.

For the quarter ended March 31, 2012 cash provided by operating activities was \$60.6 million and capital expenditure was \$6.5 million. In addition, the Company invested \$48.6 million on the acquisitions of Beijing Wits Medical Consulting Ltd and PriceSpective LLC. The Company also expended \$1.4 million on a stock repurchase programme. As a result the company's net cash amounted to \$186.0 million at March 31, 2012 compared to \$174.2 million of net cash at December 31, 2011.

Commenting on the results, Chief Executive Officer, Ciaran Murray, said "We continue to see the benefits of our strategic investment decisions, with record gross business wins of \$485 million, resulting in a backlog increase of 23% year on year, revenue of \$252 million up 10% on last year and earnings of 15 cents."

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), this press release contains certain non-GAAP financial measures, including non-GAAP operating and net income and non-GAAP diluted earnings per share. While non-GAAP financial measures are not superior to or a substitute for the comparable GAAP measures, ICON believes certain non-GAAP information is useful to investors for historical comparison purposes.

The company will hold its fourth quarter conference call today, April 24, 2012 at 9:00 EST [14:00 Ireland & UK]. This call and associated slide presentation can be accessed live from our website at http://www.iconplc.com. A recording will also be available on the website for 90 days following the call. In addition, a calendar of company events, including upcoming conference presentations, is available on our website under "Investors". This calendar will be updated regularly.

The statements made in this press release may contain forward-looking statements that involve a number of risks and uncertainties. In addition to the matters described in this Press Release, the ability to maintain large client contracts or enter into new contracts, maintain client relationships and the ability to manage the opening of new offices, the integration of new business mergers and acquisitions, as well as other risks and uncertainties detailed from time to time in SEC reports filed by ICON, including its Form 20-F, F-1, S-8 and F-3, may affect the actual results achieved by ICON. ICON disclaims any intent or obligation to update these forward-looking statements.

ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 84 locations in 40 countries and has approximately 8,670 employees. Further information is available at <a href="https://www.iconplc.com">www.iconplc.com</a>.

Source: ICON plc

Contact : Investor Relations 1-888-381-7923 or

Brendan Brennan Chief Financial Officer + 353 -1-291-2000

Sam Farthing VP Investor Relations + 353 –1-291-2000

All at ICON.

#### ICON plc

# Consolidated Income Statements (Unaudited) (Before non-recurring Charges)

#### Three Months ended March 31, 2012 and March 31, 2011 (Dollars, in thousands, except share and per share data)

	Three Months Ended March 31, March 31,	
	2012	2011
Gross Revenue	343,055	305,547
Reimbursable expenses	90,722	76,250
Net Revenue	252,333	229,297
<b>Costs and expenses</b> Direct costs Selling, general and administrative Depreciation and amortization	162,284 67,515 10,802	144,470 59,883 8,973
Total costs and expenses	240,601	213,326
Income from operations	11,732	15,971
Net interest (expense)/income	(35)	66
Income before provision for income taxes	11,697	16,037
Provision for income taxes	2,726	3,231
Net income	8,971	12,806
Net income per ordinary share Basic	\$0.15	\$0.21
Diluted	\$0.15	\$0.21
Weighted average number of ordinary shares Basic	60,086,104	60,283,078
Diluted	60,708,469	60,982,948

# ICON plc

# Consolidated Income Statements (Unaudited) (US GAAP)

#### Three Months ended March 31, 2012 and March 31, 2011 (Dollars, in thousands, except share and per share data)

	Three Mon March 31, 2012	ths Ended March 31, 2011
Gross Revenue	343,055	305,547
Reimbursable expenses	90,722	76,250
Net Revenue	252,333	229,297
Costs and expenses Direct costs Selling, general and administrative Depreciation and amortization Non-recurring charges Total costs and expenses	162,284 67,515 10,802 - 240,601	144,470 59,883 8,973 5,002 218,328
Income from operations	11,732	10,969
Net interest (expense)/income	(35)	66
Income before provision for income taxes	11,297	11,035
Provision for income taxes Net income	2,726 8,971	2,687 8,348
Net income per ordinary share Basic	\$0.15	\$0.14
Diluted	\$0.15	\$0.14
Weighted average number of ordinary shares Basic	60,086,104	60,283,078
Diluted	60,708,469	60,982,948

#### ICON plc

#### Summary Balance Sheet Data

#### March 31, 2012 and December 31, 2011 (Dollars, in thousands)

Cash and short-term investments net of debt	March 31, 2012 (Unaudited) 185,994	December 31, 2011 (Audited) 174,177
Accounts receivable Unbilled revenue Payments on account Total	195,094 113,141 (168,764) 139,471	201,338 126,850 (150,792) 177,396
Working Capital	201,821	253,514
Total Assets	1,125,506	1,035,467
Shareholder's Equity	701,774	681,544

Source:

Contact:

#### ICON plc

Investor Relations 1-888-381-7923 or Brendan Brennan CFO + 353 1 291 2000 Sam Farthing VP IR +353 1 291 2000 All at ICON.

http://www.iconplc.com

CONTACT: Icon PLC